Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35452089.
- Also identified by DOI 10.1001/jamaoncol.2022.1467 and PMC identifier 12244246.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study examines cellular and humoral pathways at 6 months after BNT162b2 COVID-19 vaccination in patients with cancer who were receiving active antineoplastic treatment.
Medical subject headings
- Neoplasms
- Vaccines